Medicare AdvantageDocumentationMedium impact
MA08.124e, Cemiplimab-rwlc (Libtayo®)
Independence Blue Cross·Oncology, Dermatology·Pharmacy
Effective date
Dec 29, 2025
We identified it
Jun 19, 2026
Summary
Policy MA08.124e updates medical necessity criteria, medical coding guidelines, and general informational content for Cemiplimab-rwlc (Libtayo®), a PD-L1 inhibitor immunotherapy. This recent change (effective 12/29/2025) affects how this drug is authorized, coded, and billed for Medicare Advantage members. The billing team must review updated criteria to ensure claims comply with new medical necessity standards.
Action Required
By 12/29/2025: Billing and prior authorization teams must review the full policy text at the provided URL to identify specific medical necessity criteria, coding requirements, and any documentation changes for Cemiplimab-rwlc (Libtayo®). Update internal billing guidelines, prior authorization workflows, and any relevant EMR templates or decision support tools to reflect the new criteria. Verify that all claims for this drug include required medical necessity documentation. Communicate changes to providers and clinical staff. Failure to align with updated criteria may result in claim denials or recoupment.